Increased receptor binding capability of the SARS-CoV-2 saltational variant PJ.2.1

Abstract

The recently identified SARS-CoV-2 saltational variant PJ.2.1, a highly mutated descendant of MC.10.1, has achieved rapid intercontinental spread since its detection in May 2026. Here, we show that PJ.2.1 exhibits exceptionally high human ACE2-binding capability, significantly outperforming contemporary variants such as NB.1.8.1, XFG, and BA.3.2.2. However, despite acquiring over 25 spike mutations, PJ.2.1 remains antigenically similar to the circulating JN.1 family and does not display strong humoral immune evasion. Neutralization profiling indicates that PJ.2.1 possesses heightened neutralization sensitivity to human plasma and RBD-targeting antibodies, especially against cryptic-site-targeting class 4 and class 5 antibodies. This distinct sensitivity profile strongly suggests an altered spike structural dynamic that favors a receptor-accessible "up" conformation. While PJ.2.1 currently lacks the extreme immune evasion capabilities of other contemporary strains, its robust baseline receptor binding strength mirrors the early evolutionary trajectory of BA.2.86 to JN.1. This high receptor binding affinity provides a structural buffer that could facilitate the rapid acquisition of potent immune-evasive mutations, necessitating continued genomic, epidemiological, and virological surveillance of PJ.2.1.

Imbalance between RNA-binding proteins and the WAVE regulatory complex underlies the toxic gain-of-function effects of the CYFIP2 Arg87Cys variant in neurodevelopmental disorders
U. S. Kim, Y. Jun, H. Kim +14
bioRxiv27 Oct 2026PreprintAll rights reservedFull textNeurosciencebioRxiv
Neurokinin 1 receptor blockade is associated with increased survival of patients with C. difficile infection
L. Zhao, M. Liu, S. Wang +8
bioRxiv6 Sep 2026PreprintCC BY-NC-NDFull textMicrobiologybioRxiv
Antibody evasion and receptor binding of SARS-CoV-2 RW.1.1
K. Daniel, H. Hong, C.-Y. Huang +4
bioRxiv10 Sep 2026PreprintAll rights reservedFull textMicrobiologybioRxiv
Antibody 3CF5 neutralizes historical and emerging H5Nx influenza viruses by targeting a conserved non-receptor-binding hemagglutinin epitope
Huan Liang, Chuanying Niu, Yuanyi Cheng +16
Cell Reports30 Oct 2026Peer-reviewedCC BY-NC-ND 4.0General biologyCrossref
Reducing dietary acid-binding capacity of low-zinc diets increased growth performance of weaned pigs in a commercial environment.
L Zhu, L F Wang, J L Landero +3
Translational animal science15 Oct 2026Peer-reviewedCC BY-NCFull textZoology & animal behaviourEurope PMCPMC

Cite

BibTeX RIS

BibTeX

@misc{he2026increased,
  title = {{Increased receptor binding capability of the SARS-CoV-2 saltational variant PJ.2.1}},
  author = {P. He and B. Li and C. Guo and L. Yu and Y. Yu and F. Jian and F. Shao and Y. Cao},
  howpublished = {bioRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.03.749172},
  url = {https://www.biorxiv.org/content/10.64898/2026.09.03.749172v1},
  note = {CC BY-NC},
}

RIS

TY  - UNPB
TI  - Increased receptor binding capability of the SARS-CoV-2 saltational variant PJ.2.1
AU  - P. He
AU  - B. Li
AU  - C. Guo
AU  - L. Yu
AU  - Y. Yu
AU  - F. Jian
AU  - F. Shao
AU  - Y. Cao
PY  - 2026
DA  - 2026/09/03
PB  - bioRxiv
DO  - 10.64898/2026.09.03.749172
UR  - https://www.biorxiv.org/content/10.64898/2026.09.03.749172v1
AB  - The recently identified SARS-CoV-2 saltational variant PJ.2.1, a highly mutated descendant of MC.10.1, has achieved rapid intercontinental spread since its detection in May 2026. Here, we show that PJ.2.1 exhibits exceptionally high human ACE2-binding capability, significantly outperforming contemporary variants such as NB.1.8.1, XFG, and BA.3.2.2. However, despite acquiring over 25 spike mutations, PJ.2.1 remains antigenically similar to the circulating JN.1 family and does not display strong humoral immune evasion. Neutralization profiling indicates that PJ.2.1 possesses heightened neutralization sensitivity to human plasma and RBD-targeting antibodies, especially against cryptic-site-targeting class 4 and class 5 antibodies. This distinct sensitivity profile strongly suggests an altered spike structural dynamic that favors a receptor-accessible "up" conformation. While PJ.2.1 currently lacks the extreme immune evasion capabilities of other contemporary strains, its robust baseline receptor binding strength mirrors the early evolutionary trajectory of BA.2.86 to JN.1. This high receptor binding affinity provides a structural buffer that could facilitate the rapid acquisition of potent immune-evasive mutations, necessitating continued genomic, epidemiological, and virological surveillance of PJ.2.1.
ER  -

Abstract

Related

Cite